TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and R...
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: GlobeNewswire
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 26 – 28, 2022, in Amsterdam, the Netherlands. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at https://journals.sagepub.com/doi/epub/10.1177/13524585221123687. Details of the presentations are outlined below. PRESENTATIONS: Poster Presentation Title: Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of ublituximab Versus teriflunomide in Participants With Relapsing Multiple Sclerosis Presentation Date/Time: Wednesday, October 26, 2022 / 16:30 - 18:30 CEST / 10:30 am – 12:30pm ETSession: Poster Session 1,
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics: The Cloud Over Briumvi [Seeking Alpha]Seeking Alpha
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- TG Therapeutics: BRIUMVI Development Could Lead To Great Results [Seeking Alpha]Seeking Alpha
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/28/24 - Beat
TGTX
Sec Filings
- 3/15/24 - Form 4
- 3/13/24 - Form 4
- 3/13/24 - Form 144
- TGTX's page on the SEC website